Management of Uncontrollable Blood Pressure in Pregnancy

Definition and Criteria

Uncontrollable blood pressure in pregnancy is defined as the inability to control maternal blood pressure despite using ≥3 classes of antihypertensive medications in appropriate doses, which constitutes an indication for delivery, as per the International Society for the Study of Hypertension in Pregnancy (ISSHP) guidelines 1, 2, 3
The ISSHP provides the most explicit definition, requiring ≥3 different drug classes and appropriate dosing of each medication, with clinical significance representing a maternal indication for delivery regardless of gestational age 1, 2, 3

Blood pressure ≥160/110 mmHg requires urgent treatment in a monitored setting, as this threshold is associated with increased stroke risk and represents a hypertensive emergency in the context of preeclampsia/eclampsia, according to the European Heart Journal and Hypertension guidelines 1, 2, 3, 4
First-line agents for acute severe hypertension include oral nifedipine and intravenous labetalol or hydralazine, as recommended by the Hypertension journal 6
The treatment goal for acute severe hypertension is to reduce systolic blood pressure to 140-150 mmHg and diastolic blood pressure to 90-100 mmHg, although the specific citation for this is not provided, the context is from the Hypertension journal discussions 6
Blood pressure consistently ≥140/90 mmHg should be treated to reduce the likelihood of developing severe maternal hypertension and associated complications, as per the Hypertension journal guidelines 1, 2, 3, 6
The target blood pressure for ongoing management is diastolic blood pressure of 85 mmHg and systolic blood pressure of 110-140 mmHg, as recommended by the Hypertension journal and ISSHP guidelines 1, 2, 3, 6, 7

Acceptable first-line oral agents for non-urgent treatment include methyldopa, labetalol, and long-acting nifedipine formulations, as recommended by the Hypertension journal and ISSHP guidelines 6, 8
Second or third-line agents include hydralazine and prazosin, as per the Hypertension journal guidelines 6

Antihypertensive drugs should be reduced or ceased if diastolic blood pressure falls <80 mmHg to avoid maternal hypotension and potential placental hypoperfusion, as recommended by the Hypertension journal 6
The CHIPS trial demonstrated that development of severe hypertension was associated with significantly greater likelihood of adverse outcomes for both mother and baby, supporting the rationale for tight blood pressure control, as per the Hypertension journal guidelines 1, 2, 3, 7